QHSLab, Inc. Reports 32% Year-Over-Year Revenue Growth and Expanded Gross Margins in First Quarter 2025
QHSLab Inc. (USAQ) reported strong financial results for Q1 2025, with total revenue increasing 32.1% year-over-year to $645,419, up from $488,587 in Q1 2024. The company's gross profit rose to $429,944, with gross margin expanding to 66.6% from 58.6% in the prior year.
The growth was driven by multiple revenue streams, including a 28% increase in Integrated Service Program (ISP) revenue to $162,502, an 11.7% increase in Allergy Diagnostic Kit sales to $264,913, and new revenue of $89,100 from clinical study performance obligations. The improved gross margin reflects favorable product mix and operational synergies across the company's core offerings in digital health and diagnostic tools for primary care.
While most segments showed growth, subscription revenue declined by 49.5% to $9,285. The company expects continued variability in gross margin depending on product mix and pricing but maintains its focus on long-term profitability and scale.
QHSLab Inc. (USAQ) ha riportato risultati finanziari solidi per il primo trimestre del 2025, con un fatturato totale in aumento del 32,1% su base annua, raggiungendo $645.419, rispetto a $488.587 nel primo trimestre del 2024. Il profitto lordo dell'azienda è salito a $429.944, con un margine lordo che si è ampliato al 66,6% dal 58,6% dell'anno precedente.
La crescita è stata trainata da diverse fonti di ricavo, inclusi un aumento del 28% dei ricavi del Programma di Servizio Integrato (ISP) a $162.502, un incremento dell'11,7% nelle vendite dei Kit Diagnostici per Allergie a $264.913, e nuovi ricavi per $89.100 derivanti da obblighi di prestazione di studi clinici. Il miglioramento del margine lordo riflette una combinazione favorevole di prodotti e sinergie operative nelle offerte principali dell’azienda nel campo della salute digitale e degli strumenti diagnostici per la medicina primaria.
Nonostante la crescita nella maggior parte dei segmenti, i ricavi da abbonamenti sono diminuiti del 49,5%, scendendo a $9.285. L’azienda prevede una continua variabilità del margine lordo in base alla composizione dei prodotti e ai prezzi, ma mantiene il focus sulla redditività e sulla crescita a lungo termine.
QHSLab Inc. (USAQ) reportó sólidos resultados financieros para el primer trimestre de 2025, con ingresos totales que aumentaron un 32,1% interanual hasta $645,419, desde $488,587 en el primer trimestre de 2024. La ganancia bruta de la empresa subió a $429,944, con un margen bruto que se expandió al 66,6% desde el 58,6% del año anterior.
El crecimiento fue impulsado por múltiples fuentes de ingresos, incluyendo un aumento del 28% en los ingresos del Programa de Servicio Integrado (ISP) hasta $162,502, un incremento del 11,7% en las ventas de Kits Diagnósticos de Alergias hasta $264,913, y nuevos ingresos de $89,100 provenientes de obligaciones de desempeño en estudios clínicos. La mejora en el margen bruto refleja una combinación favorable de productos y sinergias operativas en las ofertas principales de la empresa en salud digital y herramientas diagnósticas para atención primaria.
Aunque la mayoría de los segmentos mostraron crecimiento, los ingresos por suscripciones disminuyeron un 49,5% hasta $9,285. La empresa espera una variabilidad continua en el margen bruto dependiendo de la mezcla de productos y precios, pero mantiene su enfoque en la rentabilidad y el crecimiento a largo plazo.
QHSLab Inc. (USAQ)는 2025년 1분기에 강력한 재무 실적을 보고했으며, 총 매출은 전년 동기 대비 32.1% 증가한 $645,419로, 2024년 1분기의 $488,587에서 상승했습니다. 회사의 총 이익은 $429,944로 증가했으며, 총 마진은 전년도의 58.6%에서 66.6%로 확대되었습니다.
성장은 여러 수익원에 힘입었으며, 통합 서비스 프로그램(ISP) 수익이 28% 증가하여 $162,502를 기록했고, 알레르기 진단 키트 판매는 11.7% 증가한 $264,913에 달했으며, 임상 연구 수행 의무에서 발생한 신규 수익은 $89,100였습니다. 개선된 총 마진은 유리한 제품 구성과 디지털 헬스 및 1차 진료용 진단 도구에 대한 회사의 핵심 제품 간 운영 시너지 효과를 반영합니다.
대부분의 부문이 성장세를 보였지만, 구독 수익은 49.5% 감소하여 $9,285로 줄었습니다. 회사는 제품 구성과 가격에 따라 총 마진 변동성이 지속될 것으로 예상하지만, 장기적인 수익성과 규모 확대에 집중하고 있습니다.
QHSLab Inc. (USAQ) a publié de solides résultats financiers pour le premier trimestre 2025, avec un chiffre d'affaires total en hausse de 32,1% en glissement annuel à 645 419 $, contre 488 587 $ au premier trimestre 2024. Le bénéfice brut de l'entreprise a augmenté pour atteindre 429 944 $, avec une marge brute passant de 58,6% à 66,6%.
Cette croissance a été portée par plusieurs sources de revenus, notamment une augmentation de 28% des revenus du Programme de Service Intégré (ISP) à 162 502 $, une hausse de 11,7% des ventes de kits de diagnostic allergique à 264 913 $, ainsi que de nouveaux revenus de 89 100 $ provenant des obligations de performance liées aux études cliniques. L'amélioration de la marge brute reflète un mix produit favorable et des synergies opérationnelles au sein des offres principales de l'entreprise dans la santé numérique et les outils diagnostiques pour les soins primaires.
Alors que la plupart des segments ont connu une croissance, les revenus d'abonnement ont diminué de 49,5% pour s'établir à 9 285 $. L'entreprise s'attend à une variabilité continue de la marge brute en fonction du mix produit et des prix, tout en restant concentrée sur la rentabilité et la croissance à long terme.
QHSLab Inc. (USAQ) meldete starke Finanzergebnisse für das erste Quartal 2025, mit einem Gesamtumsatz, der um 32,1% im Jahresvergleich auf $645.419 gestiegen ist, gegenüber $488.587 im ersten Quartal 2024. Der Bruttogewinn des Unternehmens stieg auf $429.944, wobei die Bruttomarge von 58,6% im Vorjahr auf 66,6% anstieg.
Das Wachstum wurde durch mehrere Einnahmequellen getrieben, darunter ein 28%iger Anstieg der Einnahmen aus dem Integrierten Serviceprogramm (ISP) auf $162.502, ein 11,7%iger Anstieg der Verkäufe von Allergiediagnosekits auf $264.913 sowie neue Einnahmen von $89.100 aus Leistungszusagen klinischer Studien. Die verbesserte Bruttomarge spiegelt eine günstige Produktmischung und operative Synergien in den Kernangeboten des Unternehmens im Bereich digitale Gesundheit und diagnostische Werkzeuge für die Primärversorgung wider.
Während die meisten Segmente Wachstum zeigten, gingen die Abonnementerlöse um 49,5% auf $9.285 zurück. Das Unternehmen erwartet weiterhin Schwankungen der Bruttomarge, abhängig von Produktmix und Preisgestaltung, bleibt jedoch auf langfristige Rentabilität und Wachstum fokussiert.
- Revenue grew 32.1% year-over-year to $645,419
- Gross margin expanded significantly to 66.6% from 58.6%
- ISP revenue increased 28% to $162,502
- Allergy Diagnostic Kit sales grew 11.7% to $264,913
- New revenue stream from clinical studies added $89,100
- Subscription revenue declined 49.5% to $9,285
- Company expects continued variability in gross margins
- Revenue increased
32% year-over-year to$645,419 , driven by growth in ISP and Allergy Diagnostics - Gross margin expanded to
66.6% , reflecting improved product mix and operational efficiencies
WEST PALM BEACH, FL, May 15, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health company advancing personalized medicine through innovative population health screening and point of care diagnostic tools in primary care, today announced its financial results for the three months ended March 31, 2025.
Financial Highlights for Q1 2025:
- Total revenue increased
32.1% to$645,419 , compared to$488,587 in Q1 2024 - Gross profit rose to
$429,944 , up from$286,158 in the prior-year period - Gross margin expanded to
66.6% , from58.6% in Q1 2024
The strong year-over-year growth was driven by a diversified revenue base including:
- A
28.0% increase in Integrated Service Program (ISP) revenue to$162,502 - An
11.7% increase in Allergy Diagnostic Kit sales to$264,913 - New revenue of
$89,100 from the achievement of clinical study performance obligations
| Revenue Breakdown | Q1 2025 | Q1 2024 | % Change | |||||||||
| Allergy Diagnostics | $ | 264,913 | $ | 237,066 | +11.7 | % | ||||||
| ISP Services | $ | 162,502 | $ | 127,004 | +28.0 | % | ||||||
| Immunotherapy | $ | 97,329 | $ | 86,325 | +12.8 | % | ||||||
| Clinical Study | $ | 89,100 | – | New | ||||||||
| Subscriptions | $ | 9,285 | $ | 18,370 | -49.5 | % | ||||||
| Shipping & Handling | $ | 9,970 | $ | 9,959 | – | |||||||
| Training & Other | $ | 12,320 | $ | 9,863 | +24.9 | % | ||||||
| Total | $ | 645,419 | $ | 488,587 | +32.1 | % | ||||||
“We’re pleased to report strong top-line growth and a significant improvement in gross profitability for the first quarter,” said Troy Grogan, CEO of QHSLab. “Our multi-pronged revenue model is beginning to show the structural advantages we anticipated. As our integrated clinical services and diagnostics continue gaining traction in primary care, we’re focused on driving sustainable margin expansion and unlocking shareholder value.”
The increase in gross margin reflects a favorable product mix, operational synergies across the company’s core offerings, and increased revenue from high-margin services such as ISP and clinical research contracts. QHSLab expects continued variability in gross margin depending on timing and mix of new product introductions, customer profile, and negotiated pricing, but remains focused on achieving long-term profitability and scale.
For more information about QHSLab and our healthcare solutions, please visit www.qhslab.com.
About QHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues.
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Brett Maas, Managing Principal, Hayden IR, LLC
brett@haydenir.com
646-536-7331
https://twitter.com/QHSLabInc
FAQ
What was QHSLab's (USAQ) revenue growth in Q1 2025?
How much did USAQ's gross margin improve in Q1 2025?
What were the main revenue drivers for QHSLab in Q1 2025?
Which segment showed the strongest growth for USAQ in Q1 2025?
Did any of QHSLab's revenue segments decline in Q1 2025?
